



IEO

European Institute of Oncology



Milan, October 2nd - 3rd, 2026

NLMSF International Leiomyosarcoma Roundtable

Addressing the unanswered questions in Leiomyosarcoma

SCIENTIFIC COMMITTEE AND
PROGRAM COORDINATORS

Roberta Sanfilippo

Elise F. Nassif Haddad

Ryan Austin Denu

Tom Wei-Wu Chen



FACULTY

Course Director

Roberta Sanfilippo
Director, Sarcoma Unit,
IRCCS IEO, Milan, Italy

Elise F. Nassif Haddad
The University of Texas MD
Anderson Cancer Center,
Houston, TX, USA

Ryan Austin Denu
Assistant Professor
Department of Medicine
Carbone Cancer Center
University of Wisconsin-
Madison

Tom Wei-Wu Chen
National Taiwan University
Hospital and National Taiwan
University College of Medicine,
Taipei, Taiwan

NLMSF Leadership

Annie Achee
President, NLMS Foundation,
Denver, CO, USA

Mitch Achee
Co-President, NLMS
Foundation, Denver, CO, USA

Local hosts and institutional welcome

Roberto Orecchia
Scientific Director,
IRCCS IEO, Milan, Italy

Giuseppe Curigliano
Director of New Drug
Development for Innovative
Therapies,
Scientific Deputy Director
IRCCS IEO, Milan, Italy

Faculty directory

Albiruni Ryan Abdul Razak
Princess Margaret Cancer
Centre and Sinai Health,
University of Toronto, Toronto,
Canada

Francesco Alessandrino
Department of Radiology,
University of Miami Miller
School of Medicine, Miami,
FL, USA

Jean-Yves Blay
Centre Léon Bérard, Lyon,
France

Dario Callegaro
Fondazione IRCCS Istituto
Nazionale dei Tumori, Milan,
Italy

Paolo Giovanni Casali
Fondazione IRCCS Istituto
Nazionale dei Tumori,
University of Milan, Milan,
Italy

Priya Chudasama
German Cancer Research
Center (DKFZ) and National
Center for Tumor Diseases
(NCT), Heidelberg, Germany

Sabrina Croce
Pathologist Head of
Gynecopathology Unit,
Institut Bergonié, Bordeaux,
France

Gina D'Amato
Sylvester Comprehensive
Cancer Center, University of
Miami, Miami, FL, USA

Sandra P. D'Angelo
Memorial Sloan Kettering
Cancer Center, New York, NY,
USA

Andrea Franza
Sarcoma Unit, IRCCS IEO,
Milan, Italy

Serena Garofalo
Fondazione Policlinico
Universitario Campus Bio-
Medico, Rome, Italy

Suzanne George
Dana-Farber Cancer Institute,
Boston, MA, USA

Rebecca Gladly
Mount Sinai Hospital, Sinai
Health; University of Toronto,
Toronto, Canada

Alessandro Gronchi
Fondazione IRCCS Istituto
Nazionale dei Tumori,
Milan, Italy

Matthew L. Hemming
UMass Chan Medical School
and UMass Memorial Health,
Worcester, MA, USA

Paul Huang
The Institute of Cancer
Research and The Royal
Marsden, London, UK

Matthew Alfred Ingham
Perlmutter Cancer Center, NYU
Langone Health, New York,
NY, USA

Antoine Italiano
Department of Medical
Oncology - Sarcomas, Institut
Bergonié, Bordeaux, France

Robin Lewis Jones
The Royal Marsden NHS
Foundation Trust and The
Institute of Cancer Research,
London, UK

Bernd Kasper
Mannheim Cancer Center,
University Medical Center
Mannheim, Mannheim,
Germany

Nicolas Jose Llosa
Johns Hopkins University
School of Medicine, Baltimore,
MD, USA

Herbert Ho Fung Loong
Department of Clinical
Oncology, The Chinese
University of Hong Kong, Hong
Kong SAR, China

Robert G. Maki
Memorial Sloan Kettering
Cancer Center, New York, NY,
USA

Alessandra Maleddu
University of Colorado
Anschutz Medical Campus,
Aurora, CO, USA

Javier Martín-Broto
Hospital Universitario
Fundación Jiménez Díaz /
ATBSarc, Madrid, Spain

Aisha Miah
The Royal Marsden NHS
Foundation Trust and The
Institute of Cancer Research,
London, UK

Everett J. Moding
Department of Radiation
Oncology, Stanford University
School of Medicine, Stanford,
CA, USA

Sujana Movva
Memorial Sloan Kettering
Cancer Center

Fabio Murtas
Sarcoma Unit,
IRCCS IEO, Milan, Italy

Scott H. Okuno
Mayo Clinic Comprehensive
Cancer Center, Rochester, MN,
USA

Sandro Pasquali
Fondazione IRCCS Istituto
Nazionale dei Tumori, Milan,
Italy

Elisabetta Pennacchioli
Director, Melanoma and
Sarcoma Surgery,
IRCCS IEO, Milan, Italy

Seth Michaels Pollack
Robert H. Lurie Comprehensive
Cancer Center, Northwestern
University, Chicago, IL, USA

Joanna Przybyl
McGill University and Research
Institute of the McGill
University Health Centre /
Computational Life Sciences,
Cleveland Clinic
Montreal, Canada

Denise Reinke
Sarcoma Patient Advocacy
Global Network (SPAGN)

Inga-Marie Schaefer
Brigham and Women's
Hospital, Harvard Medical
School and Dana-Farber Cancer
Institute, Boston, MA, USA

Brittany L. Siontis
Mayo Clinic, Rochester, MN,
USA

Silvia Stacchiotti
Fondazione IRCCS Istituto
Nazionale dei Tumori, Milan,
Italy

David M. Thomas
University of New South Wales
and Omico, Sydney, Australia

Gabriele Tinè
Biostatistics for Clinical
Research Unit, Fondazione
IRCCS Istituto Nazionale dei
Tumori, Milan, Italy

Carlos Torrado
The University of Texas MD
Anderson Cancer Center,
Houston, TX, USA

Jonathan C. Trent
Sylvester Comprehensive
Cancer Center, University
of Miami Miller School of
Medicine, Miami, FL, USA

Raul F. Valenzuela Perez
Department of Musculoskeletal
Imaging, The University of
Texas MD Anderson Cancer
Center, Houston, TX, USA

Winar J. van Houdt
Netherlands Cancer Institute,
Amsterdam, The Netherlands

Julien Vibert
Gustave Roussy, Villejuif,
France

Breelyn Ann Wilky
University of Colorado
Anschutz Medical Campus,
Aurora, CO, USA

Agnieszka Wozniak
KU Leuven, Leuven, Belgium

Scientific Program

DAY 1 - Friday, October 2nd

Welcome & Opening Remarks

8.30 Institutional welcome
Roberto Orecchia, Giuseppe Curigliano, Roberta Sanfilippo

8.40 From patients to priorities: the origin of the NLMS Foundation and its mission in Leiomyosarcoma
Annie Achee

8.50 The SPAGN perspective: bringing the global patient voice to LMS research and care
Denise Reinke

SESSION I - Defining the unanswered questions from a clinical point of view
Unanswered questions in Leiomyosarcoma from a clinical point of view
Chair: Suzanne George
Moderators: Elisabetta Pennacchioli, Winan J. van Houdt

9.00 Leiomyosarcoma today: progress, paradoxes, and paths forward
Suzanne George

Unmet clinical needs across LMS disease settings

9.15 The surgical oncologist's point of view
Alessandro Gronchi

9.25 The radiation oncologist's point of view
Aisha Miah

9.35 The medical oncologist's point of view
Tom Wei-Wu Chen

9.45 Decision-making in the absence of evidence
Paolo Giovanni Casali

10.00 Plenary discussion: ideas to address clinical unmet needs
Suzanne George

10.30 Coffee break

SESSION II - Unanswered questions in gynecological leiomyosarcoma: when LMS is not one disease
Uterine LMS and STUMP as a Paradigm of Clinical Complexity
Chair: Roberta Sanfilippo
Moderator: Sabrina Croce, Suzanne George

10.45 From diagnostic uncertainty to risk stratification in uterine Leiomyosarcoma
Sabrina Croce

11.00 Risk stratification in uterine LMS: why predicting outcome remains so difficult
Andrea Franza

11.15 Learning from other sarcoma models: the Sarculator experience
Dario Callegaro

11.25 Strengths and limitations of prognostic tools
Gabriele Tinè

11.35 From unanswered questions to a shared solution: launching a nomogram for uterine Leiomyosarcoma as a collaborative initiative
Serena Garofalo, Roberta Sanfilippo

Scientific Program

Integrated Module - Radiology and Radiomics

- 11.45 Diagnostic radiology and radiomics in uterine LMS and STUMP: can imaging contribute to risk prediction and biological stratification?
Imaging perspective: *Raul Valenzuela Perez*
Radiomics perspective: *Raul Valenzuela Perez*
- 12.05 Panel discussion
Led by Roberta Sanfilippo with *Sabrina Croce, Suzane George*
- 12.30 Light lunch

SESSION III - Unanswered biological questions: can models, multi-omics and radiomics converge to unlock LMS biology?

Understanding Leiomyosarcoma Biology to Drive Therapeutic Innovation

Chair: *Priya Chudasama*
Modetators: *Rebecca Gladdy, Sandro Pasquali, Inga-Marie Schaefer*

- 13.30 Understanding LMS biology to to drive therapeutic innovation
Inga-Marie Schaefer
- 13.45 LMS preclinical models: what they explain and what they fail to predict
Matthew L. Hemming
- 13.55 From preclinical models to therapeutic opportunities in Leiomyosarcoma
Agnieszka Wozniak
- 14.05 AI, Single-Cell and Spatial Omics: New Tools to Dissect Leiomyosarcoma Heterogeneity
Julien Vibert

- 14.15 Genomic clues to trial design
Jonathan C. Trent

- 14.25 Cellular Plasticity in LMS
Ryan Austin Denu

Integrated Module - Radiology and Radiomics

- 14.35 Radiomics in Leiomyosarcoma: stratification tool or descriptive exercise?
Francesco Alessandrino

- 14.45 Panel discussion
Led by *Priya Chudasama* with *Inga-Marie Schaefer, Rebecca Gladdy, and Sandro Pasquali*

- 15.15 Coffee Break

SESSION IV - Unanswered questions in emerging therapies: is there room for progress in Leiomyosarcoma?

Targets, Immunotherapy and Emerging Treatment Strategies in LMS

Chair: *Sandra D'Angelo*
Moderators: *Javier Martín-Broto, Seth M. Pollack*

- 15.45 Targets, immunotherapy and emerging treatment strategies in LMS
Sandra D'Angelo
- 16.00 Unanswered questions in LMS immune targeting
Breelyn Ann Wilky
- 16.15 The immune microenvironment of Leiomyosarcoma: new biological insights and therapeutic implications
Seth M. Pollack
- 16.30 Emerging Immune Targets in LMS
Nicolas Jose Llosa

Scientific Program

DAY 2 - Saturday, October 3rd

- 16.45 ADCs and emerging biomarker-driven therapeutics in LMS: is there room for clinical impact?
Carlos Torrado

- 17.00 Panel discussion
Led by *Sandra D'Angelo* with
Javier Martín-Broto, Seth M. Pollack

NLMSF initiative spotlight

The LMS targets task force: from prioritization to industry dialogue
Chair: *Robert G. Maki, Scott H. Okuno*

- 18.00 Target identification: Charting the Path Forward
Albiruni Ryan Abdul Razak, Priya Chudasama

- 18.15 Open discussion
Led by *Robert G. Maki, Scott Okuno*

20.00 Social Dinner

SESSION V | How to test the unanswered questions properly?

Unanswered questions in LMS clinical trial design: are we asking the right questions?

Chair: *Elise F. Nassif Haddad*

Moderators: *Albiruni Ryan Abdul Razak, Gina D'Amato*

- 9.00 Clinical trials in rare disease: endpoints and regulatory agency issues
Silvia Stacchiotti

- 9.15 Lessons from past LMS trials
Robin Lewis Jones

- 9.30 Innovative trial design in Sarcoma: what can LMS borrow from modern early-phase and histology-specific strategies?
Antoine Italiano

- 9.45 Early-phase development in Leiomyosarcoma: challenges and opportunities
Herbert Ho Fung Loong

- 10.00 Focused panel discussion: what should the next LMS trial actually look like?
Led by *Elise F. Nassif Haddad* with
Albiruni Ryan Abdul Razak, Gina D'Amato,

10.30 Coffee break

- 10.45 Hereditary predisposition and sarcoma syndromes: what do they teach us about LMS risk and biology?
David M. Thomas

Scientific Program

- 11.00 Genomics-informed outcomes in LMS: from retrospective data to prospective strategies
Robert Maki
- 11.15 ctDNA in Leiomyosarcoma: clinical promise and challenges in interpretation
Joanna Przybyl
- 11.30 Focused panel discussion
Led by *David M. Thomas with Robert G. Maki, Joanna Przybyl*

12.30 Lunch

SESSION VI - Which unanswered questions are we actively addressing? From funding to impact NLMSF-funded projects and current RFP update

Chair: *Annie Achee*

Moderators: *Matthew Alfred Ingham, Alessandra Maleddu*

- 13.45 Management of Leiomyosarcoma: consensus, controversies, and challenges
Bernd Kasper
- 13.55 Presentation of a previously funded project
Everett Moding
- 14.10 Current RFP update
Brief current RFP overview: LOIs, invited applications, proposal types, and review criteria
Matthew Alfred Ingham, Brittany L. Siontis

- 14.25 Early career awards | Early trainee award
Sujana Movva
- 14.35 Early Career Awards | Brian Van Tine Early Peer Recognition Award
Tom Wei-Wu Chen
- 14.45 Community Discussion
Led by *Annie Achee, Matthew A. Ingham, Alessandra Maleddu, Everett J. Moding*

FINAL SESSION - From discussion to roadmap

Chairs: *Jean-Yves Blay, Elise F. Nassif Haddad, Scott Okuno, Roberta Sanfilippo*

- 15.00 Priority unmet needs and collaborative trial concepts
Jean-Yves Blay
- 15.15 From unanswered questions to action: key insights and hot topics from the roundtable
Fabio Murtas
- 15.30 Cross-working group collaborative projects and trial concepts
Elise F. Nassif Haddad, Roberta Sanfilippo
- 15.45 What comes next?
Scott Okuno
- 16.15 Closing remarks
Roberta Sanfilippo

Registration fee

Free of charge

Click here to register:

<https://forms.gle/qupYSRLHg9n7mrWp7>

Certificate of attendance

The certificate will be sent via email by the Organizing Secretariat within a few days after the end of the course



Course avenue
Aula Magna Leonardo la Pietra
Edificio 1
Istituto Europeo di Oncologia
Via Ripamonti, 435 20141 Milano



Organizing Secretariat
Mz Events srl
Via C. Farini 81 – 20159 Milano
Tel. +39 3421863400
valentina.mafficini@mzevents.it

With the unconditional support of

